Thioredoxin2 enhances the damaged DNA binding activity of mtTFA through direct interaction

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1435-1440

  Kidani, Akihiko ^a,b   Izumi, Hiroto ^a   Yoshida, Yoichiro ^c   Kashiwagi, Eiji ^a   Ohmori, Haruki ^b   Tanaka, Tsuneo ^b   Kuwano, Michihiko ^d   Kohno, Kimitoshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c OSAKA ROSAI HOSPITAL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

DNA damage; Mitochondrial transcription factor A; Thioredoxin2

Indexed keywords

DNA; HIGH MOBILITY GROUP PROTEIN; MITOCHONDRIAL TRANSCRIPTION FACTOR A; THIOREDOXIN 2; ANTIOXIDANT; DNA BINDING PROTEIN; MITOCHONDRIAL PROTEIN; THIOREDOXIN; TRANSCRIPTION FACTOR; TXN2 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; HELA CELL; HIGH MOBILITY GROUP BOX DOMAIN; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; UPREGULATION; CHEMISTRY; GEL MOBILITY SHIFT ASSAY; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

AMINO ACID MOTIFS; ANTIOXIDANTS; BLOTTING, WESTERN; DNA; DNA DAMAGE; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HELA CELLS; HUMANS; IMMUNOPRECIPITATION; MITOCHONDRIAL PROTEINS; THIOREDOXINS; TRANSCRIPTION FACTORS;

EID: 73949102427     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000462     Document Type: Article

References (34)

1. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, Momii Y, Kuwano M and Kohno K: Cisplatin resistance and transcription factors. Curr Med Chem 5: 15-27, 2005.
2. Loeb LA, James EA, Waltterscorph AM and Klebanoff SJ: Mutagenesis by the autoxidation of iron with isolated DNA. Proc Natl Acad Sci USA 85: 3918-3922, 1988.
3. McBride TJ, Preston BD and Loeb LA: Mutagenic spectrum resulting from DNA damage by oxygen radicals. Biochemistry 30: 207-213, 1991.
4. Weitzman SA and Gordon LI: Inflammation and Cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76: 655-663, 1990.
5. Cortopassi GA and Arnheim N: Detection of a specific mitochondrial DNA deletion in tissues of older humans. Nucleic Acids Res 18: 6927-6933, 1990.
6. Maccabee M, Evans JS, Glackin MP, Hatahet Z and Wallace SS: Pyrimidine ring fragmentation products: effects of lesion structure and sequence context on mutagenesis. J Mol Biol 236: 514-530, 1994.
7. Soong NW, Hinton DR, Cortopassi G and Arnheim N: Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat Genet 2: 318-323, 1992.
8. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF and Wallace DC: Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet 2: 324-329, 1992.
9. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, Trush MA, Kinzler KW and Vogelstein B: Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 20: 291-293, 1998.
10. Habano W, Nakamura S and Sugai T: Microsatellite instability in the mitochondrial DNA of colorectal carcinomas: Evidence for mismatch repair systems in mitochondrial genome. Oncogene 17: 1931-1937, 1998.
11. Wallace DC: Mitochondrial diseases in man and mouse. Science 283: 1482-1488, 1999.
12. Parisi MA and Clayton DA: Similarity of human mitochondrial transcription factor 1 to high mobility group proteins. Science 252: 965-969, 1991.
13. Larsson NG, Wang J, Wilhelmsson H, Oldfors A, Rustin P, Lewandoski M, Barsh GS and Clayton DA: Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet 18: 231-236, 1998.
14. Takamatsu C, Umeda S, Ohsato T, Ohno T, Abe Y, Fukuoh A, Shinagawa H, Hamasaki N and Kang D: Regulation of mitochondrial D-loops by transcription factor A and single-stranded DNA-binding protein. EMBO Rep 3: 451-456, 2002.
15. Pil PM and Lippard SJ: Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256: 234-237, 1992.
16. Hughes EN, Engelsberg BN and Billings PC: Purification of nuclear proteins that bind to cisplatin-damaged DNA: identity with high mobility group proteins 1 and 2. J Biol Chem 267: 13520-13527, 1992.
17. Billings PC, Davis RJ, Engelsberg BN, Skov KA and Hughes EN: Characterization of high mobility group protein binding to cisplatin-damaged DNA. Biochem Biophys Res Commun 188: 1286-1294, 1992.
18. Turchi JJ, Li M and Henkels KM: Cisplatin-DNA binding specificity of calf high-mobility group 1 protein. Biochemistry 35: 2992-3000, 1996.
19. Yoshida Y, Izumi H, Ise T, Uramoto H, Torigoe T, Ishiguchi H, Murakami T, Tanabe M, Nakayama Y, Itoh H, Kasai H and Kohno K: Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA. Biochem Biophys Res Commun 295: 945-951, 2002.
20. Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y and Kohno K: Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int J Cancer 93: 869-874, 2001.
21. Fujii R, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M, Muwano M and Akiyama S: Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 85: 426-433, 1994.
22. Yoshida Y, Izumi H, Torigoe T, Ishiguchi H, Itoh H, Kang D and Kohno K: p53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res 63: 3729-3734, 2003.
23. Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yamamoto K, Funa K and Kohno K: p73 interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 277: 31694-31702, 2002.
24. Izumi H, Ohta R, Nagatani G, Ise T, Nakayama Y, Nomoto M and Kohno K: p300/CBP-associated factor (P/CAF) interacts with nuclear respiratory factor-1 to regulate the UDP-N-acetyl-α-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 gene. Biochem J 373: 713-722, 2003.
25. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Takahashi M, Naito S and Kohno K: Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 27: 5543-5553, 2008.
26. Wakasugi T, Izumi H, Uchiumi T, Suzuki H, Arao T, Nishio K and Kohno K: ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 26: 5194-5203, 2007.
27. Antoshechkin I, Bogenhagen DF and Mastrangelo IA: The HMG-box mitochondrial transcription factor xl-mtTFA binds DNA as a tetramer to activate bidirectional transcription. EMBO J 16: 3198-3206, 1997.
28. Powis G, Mustacich D and Coon A: The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29: 312-322, 2000.
29. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K and Ichijo H: Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
30. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M and Kohno K: Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55: 4293-4296, 1995.
31. Patenaude A, Murthy MRV and Mirault ME: Mitochondrial thioredoxin system; effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis. J Biol Chem 279: 27302-37314, 2004.
32. Damdimopoulos AE, Vizuete AM, Huikko MP, Gustafsson JA and Spyrou G: Human mitochondrial thioredoxin; involvement in mitochondrial membrane potential and cell death. J Biol Chem 277: 33249-33257, 2002.
33. Kalinina EV, Chernov NN, Saprin AN, Kotova YN, Gavrilova YA, Chermnykh NS and Shcherbak NP: Expression of genes for thioredoxin1 and thioredoxin2 in multidrug resistance ovarian carcinoma cells SKVLB. Bull Exp Biol Med 144: 301-303, 2007.
34. Imamura T, Izumi H, Nagatani G, Ise T, Nomoto M, Iwamoto Y and Kohno K: Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J Biol Chem 276: 7534-7540, 2001.